Performance of the new Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS amplicor HCV monitor, version 2.0, assay

被引:52
作者
Beld, M
Sentjens, R
Rebers, S
Weegink, C
Weel, J
Sol, C
Boom, R
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Sect Clin Virol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Sect Hepatol, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands
关键词
D O I
10.1128/JCM.40.3.788-793.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have evaluated the VERSANT HCV RNA 3.0. Assay (HCV 3.0 bDNA assay) (Bayer Diagnostics, Berkeley, Calif.), which is an improved signal amplification procedure for the HCV 2.0 bDNA assay for the quantitation of hepatitis C virus (HCV) RNA in serum or plasma of HCV-infected individuals. The HCV 3.0 bDNA assay has a linear dynamic range of 2.5 x 10(3) to 4.0 x 10(7) HCV RNA copies per ml (c/ml). The performance of the HCV 3.0 bDNA assay was evaluated using three different test panels. An overall specificity of 96.8% relative to the detection limit of the HCV 3.0 bDNA assay was found. The intra- and interrun reproducibilities for both the dilution panel and the NAP (AcroMetrix, Benicia, Calif.) panel were consistent with coefficients of variation of less than 9%. Quantitation with the HCV 3.0 bDNA assay was linear over the entire range of both panels (ranges of 4.4 x 10(3) to 3.5 x 10(6) c/ml and 5 x 10(3) to 2 X 10(6) Mini, respectively), with correlation coefficients of 0.999, slopes close to one, and intercepts close to zero. The regression equation indicated that 1 IU corresponded to about 4.8 copies of HCV RNA. A correlation coefficient of 0.941 was found for HCV RNA values (in international units per milliliter) obtained from the HCV 3.0 bDNA assay and the HCV Monitor version 2.0 assay (HCV Monitor 2.0 assay) (Roche Diagnostic Systems, Branchburg, N.J.). Quantitative results obtained close to the lower limit of the HCV 3.0 bDNA assay might imply that its lower limit should be reconsidered and raised, if necessary. It appeared that quantitation values obtained from the HCV Monitor 2.0 assay of between 5 X 10(2) and 10(5) IU/ml were in general higher than those obtained from the HCV 3.0 bDNA assay, whereas values obtained from the HCV Monitor 2.0 assay were underestimated for samples with HCV RNA levels above 10(5) IU/ml.
引用
收藏
页码:788 / 793
页数:6
相关论文
共 14 条
[1]   Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology [J].
Detmer, J ;
Lagier, R ;
Flynn, J ;
Zayati, C ;
Kolberg, J ;
Collins, M ;
Urdea, M ;
SanchezPescador, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 1996, 34 (04) :901-907
[2]  
EASL (European Association for the Study of the Liver), 1999, J HEPATOL S1, V31, P3
[3]   Standardized hepatitis C virus RNA panels for nucleic acid testing assays [J].
Jorgensen, PA ;
Neuwald, PD .
JOURNAL OF CLINICAL VIROLOGY, 2001, 20 (1-2) :35-40
[4]   Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics [J].
Lee, SC ;
Antony, A ;
Lee, N ;
Leibow, J ;
Yang, JQ ;
Soviero, S ;
Gutekunst, K ;
Rosenstraus, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4171-4179
[5]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[6]   Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays [J].
Mellor, J ;
Hawkins, A ;
Simmonds, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (08) :2525-2532
[7]   Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy [J].
Neumann, AU ;
Lam, NP ;
Dahari, H ;
Gretch, DR ;
Wiley, TE ;
Layden, TJ ;
Perelson, AS .
SCIENCE, 1998, 282 (5386) :103-107
[8]   Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects [J].
Nieforth, KA ;
Nadeau, R ;
Patel, IH ;
Mould, D .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (06) :636-646
[9]   Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays [J].
Pawlotsky, JM ;
Martinot-Peignoux, M ;
Poveda, JD ;
Bastie, A ;
Le Breton, V ;
Darthuy, F ;
Rémiré, J ;
Erlinger, S ;
Dhumeaux, D ;
Marcellin, P .
JOURNAL OF VIROLOGICAL METHODS, 1999, 79 (02) :227-235
[10]   Standardization of hepatitis C virus RNA quantification [J].
Pawlotsky, JM ;
Bouvier-Alias, M ;
Hezode, C ;
Darthuy, F ;
Remire, J ;
Dhumeaux, D .
HEPATOLOGY, 2000, 32 (03) :654-659